Wuxi Biologics (Cayman) Overview
Valuation check: WXXWY's ROE is 18.99%, below the Healthcare sector average of 20.86%.
Get informed when a big investor buys or sells
+ Follow18.99%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for WXXWY is 18.99%. That is below the Healthcare sector average of 20.86%. Investors often review this figure alongside Wuxi Biologics (Cayman)'s historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, WXXWY currently prints 18.99% for ROE, while the sector average sits near 20.86%. That is roughly 9.0% below the sector mean. Large gaps often invite a closer look at Wuxi Biologics (Cayman)'s growth, margins, and balance sheet.
Return on Equity shows how effectively Wuxi Biologics (Cayman) converts resources into returns. At 18.99%, WXXWY may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting WXXWY's ROE (18.99%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Wuxi Biologics (Cayman)'s ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
